Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject receiving a primary, partial liver graft from a living donor~* subject must receive the first dose of tacrolimus and corticosteroids after operation and are expected to be maintained on tacrolimus throughout the study. MMF could be combined~Exclusion Criteria:~* subjects receiving a multi-organ transplant or having previously received an organ transplant (including liver re-transplantation)~* subjects receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used~* subjects allergic or intolerant to macrolide antibiotics or tacrolimus~* subjects requiring immunosuppressive treatment and / or systemic chemotherapy prior to transplantation~* subjects with malignancies or a history of malignancy within the last 5 years, with the exception of those with basalioma or squamous cell carcinoma of the skin~* subjects with systemic infection requiring treatment, except viral hepatitis~* subjects with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus~* subjects with serum creatinine \> 1.5mg/dl~* subjects taking or having taken potassium preserved diuretics~* subjects with any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator~* subjects participating or having participated in another clinical trial and/or those taking or having taken an investigational / non-registered drug in the past 28 days~* subjects or donors known to be HIV positive~* donors known to be HBV, HCV positive and/or IgM positive of CMV, EBV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Intravenous Prograf therapy followed by oral Advagraf therapy
- Arm 2 (Type: ACTIVE_COMPARATOR): Intravenous Prograf therapy followed by oral Prograf therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).